Researchers have reported encouraging results from a new feasibility study looking to find a potential treatment for Long Covid.
The £1.2m
[ARTICLE]
"> ERASE - long COVID trial, managed by the University of Plymouth's [ARTICLE]
Peninsula Clinical Trials Unit (PenCTU) - P
"> Peninsula Clinical Trials Unit (PenCTU) and led by the University of Derby, explored whether an antiviral drug delivered intravenously could be used to treat people with Long Covid.
The study found that delivering a five-day intravenous treatment and carrying out the assessments needed to evaluate it in people with Long Covid was safe and feasible.
While the project was established to test the feasibility of using intravenous medications, researchers reported a number of encouraging changes in exploratory outcome measures, with most participants reporting reductions in fatigue, improved quality of life and increased walking distance in a timed walking test.
Now the research team is calling for a larger randomised controlled trial to establish whether the antiviral treatment is effective for people with Long Covid.
The findings have been outlined in a study published in the Oxford Open Immunology journal, and included:
- The five-day intravenous treatment regimen could be successfully delivered;
- Participants were able to complete the clinical assessments required for the research;
- The study generated important information needed to plan a larger randomised controlled trial.
/University Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.